Oncolytics Biotech (ONCY) 0.33 $ONCY
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Colorectal Cancer
PR Newswire - Thu May 19, 5:30AM CDT
REOLYSIN® Demonstrates Increase in Objective Response Rates in Female Patients and in Patients with Liver Metastases--
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer
PR Newswire - Thu May 19, 5:00AM CDT
Randomized REOLYSIN® Data Correlates Genetic Status to Patient Outcomes--
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
VIDEO: Oncolytics Biotech CEO Brad Thompson Interviewed in OTCQX Video Series
PR Newswire - Mon May 02, 6:00AM CDT
Oncolytics Biotech Inc. (TSX: ONC; OTCQX: ONCYF) CEO Brad Thompson was interviewed by OTC Markets Group Inc. (OTCQX: OTCM) in its OTCQX® Video Series. The series features one-on-one interviews with senior executives of OTCQX companies as they showcase their businesses and investment profiles.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Fri Apr 29, 11:00AM CDT
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company"
, will participate in the Bloom Burton & Co. Healthcare Investor Conference in a session on Monday, May 2nd, 2016 at 4:00 pm ET. The conference takes place on May 2nd and 3rd in Toronto, Ontario.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech(R) Inc. Announces 2015 Year End Results
PR Newswire - Fri Mar 11, 5:30AM CST
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company" today announced its financial results and operational highlights for the year ended December 31, 2015.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences
PR Newswire - Mon Feb 08, 4:21PM CST
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 18th Annual BIO CEO & Investor Conference in a session on Tuesday, February 9th, 2016 at 10:30 a.m. ET. The conference takes place on February 8th and 9th at the Waldorf Astoria in New York, NY.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Global High-Grade Glioma Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/lr2n9x/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - High-Grade Glioma Overview - Therapeutics Development - Pipeline Products for High-Grade Glioma - Overview - Pipeline Products for High-Grade Glioma - Comparative Analysis - High-Grade Glioma - Therapeutics under Development by Companies - High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes - High-Grade Glioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - High-Grade Glioma - Products under Development by Companies - High-Grade Glioma - Products under Investigation by Universities/Institutes - High-Grade Glioma - Companies Involved in Therapeutics Development - AngioChem Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Cavion LLC - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Nektar Therapeutics - Novartis AG - Oncolytics Biotech Inc. - Sanofi - Stemline Therapeutics, Inc. - Targepeutics, Inc. - Tocagen Inc. - Virttu Biologics Limited For more information visit http://www.researchandmarkets.com/research/lr...ade_glioma
MACK: 6.32 (-0.24), ONCY: 0.33 (-0.02), STML: 7.50 (-0.53), NKTR: 15.80 (-0.48), NVS: 78.94 (-1.57)
Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer
CNW Group - Tue Jan 19, 4:14PM CST
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC, OTCQX:ONCYF) today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA(®)) in combination with REOLYSIN(®) (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
ONCY: 0.33 (-0.02)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/mkmlnh/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Multiple Myeloma Overview - Therapeutics Development - Pipeline Products for Relapsed Multiple Myeloma - Overview - Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis - Relapsed Multiple Myeloma - Therapeutics under Development by Companies - Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Multiple Myeloma - Products under Development by Companies - Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - Cleave Biosciences - Curis, Inc. - Daiichi Sankyo Company, Limited - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - IGF Oncology, LLC. - Immunomedics, Inc. - Jasco Pharmaceuticals, LLC. - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Noxxon Pharma AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Sanofi For more information visit http://www.researchandmarkets.com/research/mk...d_multiple
CLRB: 3.29 (-0.15), CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), AMGN: 154.78 (-2.00), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), JNJ: 117.01 (+0.01), MRK: 56.81 (-0.37), CALA: 4.80 (-0.25), ABBV: 61.00 (+0.25), NVS: 78.94 (-1.57), EXEL: 7.38 (+0.01), ARRY: 3.51 (-0.01), CELGZ: 1.46 (-0.04)
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/t7gq4w/recurrent_head) has announced the addition of the "Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline. It provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape. - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. - The report reviews key players involved in the therapeutics development and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects. - A review of products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. - A detailed assessment of monotherapy and combination therapy pipeline projects. - Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type. Companies Mentioned: - Advaxis, Inc. - Amgen Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Genentech, Inc. - Glycotope GmbH - Immunovative Therapies, Ltd. - Laboratoires Pierre Fabre SA - Mabion SA - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Oncolytics Biotech Inc. - Ono Pharmaceutical Co., Ltd. - Panacea Biotec Limited - PCI Biotech AS - Shionogi & Co., Ltd. - Symphogen A/S - Threshold Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/t7...rrent_head
ADXS: 8.56 (-0.26), ONCY: 0.33 (-0.02), AMGN: 154.78 (-2.00), AZN: 27.97 (-0.99), MRK: 56.81 (-0.37), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), SPPI: 6.94 (-0.03), BMY: 72.65 (-0.08), STML: 7.50 (-0.53), ONTY: 1.21 (+0.02), NKTR: 15.80 (-0.48), MEIP: 1.39 (-0.02), ATNM: 1.82 (unch), ABBV: 61.00 (+0.25), EXEL: 7.38 (+0.01), NVS: 78.94 (-1.57)
MEDIA ADVISORY - Oncolytics Biotech® Inc. to Present at LD Micro Growth Conference
PR Newswire - Wed Dec 02, 5:30AM CST
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, OTCQX: ONCYF), will participate in and present at the LD Micro Conference today, Wednesday, December 2nd, 2015 at 4:00 p.m. ET. The conference takes place December 1st - 3rd in Los Angeles, CA at the Luxe Sunset Hotel.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Delisting of Securities of Daegis Inc., ZaZa Energy Corporation, Escalera Resources Co., Oncolytics Biotech, Inc., ATRM Holdings, Inc., and BG Medicine, Inc. From The Nasdaq Stock Market
GlobeNewswire - Mon Nov 23, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of Daegis Inc. Daegis Inc.'s stock was suspended on October 13, 2015 and has not traded on Nasdaq since that time.
ONCY: 0.33 (-0.02), NDAQ: 65.58 (-0.08)
/C O R R E C T I O N from Source -- Oncolytics Biotech Inc./
PR Newswire - Wed Nov 18, 4:01PM CST
In the news release, Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib, issued today by Oncolytics Biotech Inc. over CNW, we are advised by the company that the 1st paragraph, 1st sentence should have read "
VELCADE®)" rather than " Kyprolis®)" as originally issued inadvertently. The complete, corrected release follows:
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib
PR Newswire - Wed Nov 18, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC, OTCQX:ONCYF) today announced that enrollment has commenced in a Phase Ib study of REOLYSIN® combined with standard doses of bortezomib (Kyprolis®) and dexamethasone in patients with relapsed or refractory multiple myeloma (REO 019). Kevin Kelly, M.D., Ph.D. of the Keck School of Medicine of the University of Southern California (USC), is the principal investigator.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Global Oligodendroglioma Pipeline Review, H2 2015 Edition
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n9ncqk/oligodendroglioma) has announced the addition of the "Oligodendroglioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Axelar AB - Boehringer Ingelheim GmbH - Cavion LLC - Celgene Corporation - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncolytics Biotech Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. For more information visit http://www.researchandmarkets.com/research/n9...ndroglioma
ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), CLDX: 4.12 (-0.20), LLY: 73.95 (-0.48), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Oncolytics reports 3Q loss
Automated Insights - Thu Nov 05, 6:35AM CST
CALGARY, Alberta (AP) _ Oncolytics Biotech Inc. (ONCY) on Thursday reported a loss of $3.7 million in its third quarter.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
OTC Markets Group Welcomes Oncolytics Biotech® Inc. to OTCQX
PR Newswire - Thu Nov 05, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Oncolytics Biotech Inc. (TSX: ONC; OTCQX: ONCY), a Canada-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, has qualified to trade on the OTCQX® Best Market. Oncolytics previously traded on the NASDAQ Capital Market.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Colorectal Cancer
PR Newswire - Thu May 19, 5:30AM CDT
REOLYSIN® Demonstrates Increase in Objective Response Rates in Female Patients and in Patients with Liver Metastases--
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer
PR Newswire - Thu May 19, 5:00AM CDT
Randomized REOLYSIN® Data Correlates Genetic Status to Patient Outcomes--
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
VIDEO: Oncolytics Biotech CEO Brad Thompson Interviewed in OTCQX Video Series
PR Newswire - Mon May 02, 6:00AM CDT
Oncolytics Biotech Inc. (TSX: ONC; OTCQX: ONCYF) CEO Brad Thompson was interviewed by OTC Markets Group Inc. (OTCQX: OTCM) in its OTCQX® Video Series. The series features one-on-one interviews with senior executives of OTCQX companies as they showcase their businesses and investment profiles.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Fri Apr 29, 11:00AM CDT
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company"
, will participate in the Bloom Burton & Co. Healthcare Investor Conference in a session on Monday, May 2nd, 2016 at 4:00 pm ET. The conference takes place on May 2nd and 3rd in Toronto, Ontario. ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech(R) Inc. Announces 2015 Year End Results
PR Newswire - Fri Mar 11, 5:30AM CST
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company"
today announced its financial results and operational highlights for the year ended December 31, 2015. ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences
PR Newswire - Mon Feb 08, 4:21PM CST
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 18th Annual BIO CEO & Investor Conference in a session on Tuesday, February 9th, 2016 at 10:30 a.m. ET. The conference takes place on February 8th and 9th at the Waldorf Astoria in New York, NY.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Global High-Grade Glioma Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/lr2n9x/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - High-Grade Glioma Overview - Therapeutics Development - Pipeline Products for High-Grade Glioma - Overview - Pipeline Products for High-Grade Glioma - Comparative Analysis - High-Grade Glioma - Therapeutics under Development by Companies - High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes - High-Grade Glioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - High-Grade Glioma - Products under Development by Companies - High-Grade Glioma - Products under Investigation by Universities/Institutes - High-Grade Glioma - Companies Involved in Therapeutics Development - AngioChem Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Cavion LLC - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Nektar Therapeutics - Novartis AG - Oncolytics Biotech Inc. - Sanofi - Stemline Therapeutics, Inc. - Targepeutics, Inc. - Tocagen Inc. - Virttu Biologics Limited For more information visit http://www.researchandmarkets.com/research/lr...ade_glioma
MACK: 6.32 (-0.24), ONCY: 0.33 (-0.02), STML: 7.50 (-0.53), NKTR: 15.80 (-0.48), NVS: 78.94 (-1.57)
Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer
CNW Group - Tue Jan 19, 4:14PM CST
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC, OTCQX:ONCYF) today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA(®)) in combination with REOLYSIN(®) (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024). ONCY: 0.33 (-0.02)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/mkmlnh/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Multiple Myeloma Overview - Therapeutics Development - Pipeline Products for Relapsed Multiple Myeloma - Overview - Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis - Relapsed Multiple Myeloma - Therapeutics under Development by Companies - Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Multiple Myeloma - Products under Development by Companies - Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - Cleave Biosciences - Curis, Inc. - Daiichi Sankyo Company, Limited - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - IGF Oncology, LLC. - Immunomedics, Inc. - Jasco Pharmaceuticals, LLC. - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Noxxon Pharma AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Sanofi For more information visit http://www.researchandmarkets.com/research/mk...d_multiple
CLRB: 3.29 (-0.15), CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), AMGN: 154.78 (-2.00), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), JNJ: 117.01 (+0.01), MRK: 56.81 (-0.37), CALA: 4.80 (-0.25), ABBV: 61.00 (+0.25), NVS: 78.94 (-1.57), EXEL: 7.38 (+0.01), ARRY: 3.51 (-0.01), CELGZ: 1.46 (-0.04)
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/t7gq4w/recurrent_head) has announced the addition of the "Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline. It provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape. - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. - The report reviews key players involved in the therapeutics development and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects. - A review of products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. - A detailed assessment of monotherapy and combination therapy pipeline projects. - Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type. Companies Mentioned: - Advaxis, Inc. - Amgen Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Genentech, Inc. - Glycotope GmbH - Immunovative Therapies, Ltd. - Laboratoires Pierre Fabre SA - Mabion SA - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Oncolytics Biotech Inc. - Ono Pharmaceutical Co., Ltd. - Panacea Biotec Limited - PCI Biotech AS - Shionogi & Co., Ltd. - Symphogen A/S - Threshold Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/t7...rrent_head
ADXS: 8.56 (-0.26), ONCY: 0.33 (-0.02), AMGN: 154.78 (-2.00), AZN: 27.97 (-0.99), MRK: 56.81 (-0.37), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), SPPI: 6.94 (-0.03), BMY: 72.65 (-0.08), STML: 7.50 (-0.53), ONTY: 1.21 (+0.02), NKTR: 15.80 (-0.48), MEIP: 1.39 (-0.02), ATNM: 1.82 (unch), ABBV: 61.00 (+0.25), EXEL: 7.38 (+0.01), NVS: 78.94 (-1.57)
MEDIA ADVISORY - Oncolytics Biotech® Inc. to Present at LD Micro Growth Conference
PR Newswire - Wed Dec 02, 5:30AM CST
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, OTCQX: ONCYF), will participate in and present at the LD Micro Conference today, Wednesday, December 2nd, 2015 at 4:00 p.m. ET. The conference takes place December 1st - 3rd in Los Angeles, CA at the Luxe Sunset Hotel.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Delisting of Securities of Daegis Inc., ZaZa Energy Corporation, Escalera Resources Co., Oncolytics Biotech, Inc., ATRM Holdings, Inc., and BG Medicine, Inc. From The Nasdaq Stock Market
GlobeNewswire - Mon Nov 23, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of Daegis Inc. Daegis Inc.'s stock was suspended on October 13, 2015 and has not traded on Nasdaq since that time.
ONCY: 0.33 (-0.02), NDAQ: 65.58 (-0.08)
/C O R R E C T I O N from Source -- Oncolytics Biotech Inc./
PR Newswire - Wed Nov 18, 4:01PM CST
In the news release, Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib, issued today by Oncolytics Biotech Inc. over CNW, we are advised by the company that the 1st paragraph, 1st sentence should have read "
VELCADE®)" rather than " Kyprolis®)" as originally issued inadvertently. The complete, corrected release follows: ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib
PR Newswire - Wed Nov 18, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC, OTCQX:ONCYF) today announced that enrollment has commenced in a Phase Ib study of REOLYSIN® combined with standard doses of bortezomib (Kyprolis®) and dexamethasone in patients with relapsed or refractory multiple myeloma (REO 019). Kevin Kelly, M.D., Ph.D. of the Keck School of Medicine of the University of Southern California (USC), is the principal investigator. ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
Global Oligodendroglioma Pipeline Review, H2 2015 Edition
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n9ncqk/oligodendroglioma) has announced the addition of the "Oligodendroglioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Axelar AB - Boehringer Ingelheim GmbH - Cavion LLC - Celgene Corporation - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncolytics Biotech Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. For more information visit http://www.researchandmarkets.com/research/n9...ndroglioma
ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), CLDX: 4.12 (-0.20), LLY: 73.95 (-0.48), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Oncolytics reports 3Q loss
Automated Insights - Thu Nov 05, 6:35AM CST
CALGARY, Alberta (AP) _ Oncolytics Biotech Inc. (ONCY) on Thursday reported a loss of $3.7 million in its third quarter.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
OTC Markets Group Welcomes Oncolytics Biotech® Inc. to OTCQX
PR Newswire - Thu Nov 05, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Oncolytics Biotech Inc. (TSX: ONC; OTCQX: ONCY), a Canada-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, has qualified to trade on the OTCQX® Best Market. Oncolytics previously traded on the NASDAQ Capital Market.
ONCY: 0.33 (-0.02), ONC.TO: 0.50 (unch)
